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INTRODUCTION
Hepatitis B virus (HBV) is a hepatotropic, non-cy-
topathic DNA virus which has been estimated to in-
fect one third of global population, of whom 350 to 
400 million suffering from chronic infection. This 
chronicity estate is responsible for major complica-
tions of HBV infection including cirrhosis and hepa-
tocellular carcinoma.
The HBV infection prevalence in Iran has been es-
timated at 2.14% to 2.6% (1-3). This prevalence in 
males is about 25% higher than females (2.55% vs. 
2.03% rates, respectively) (1). 
According a systematic review by Alavian et al, 
about 1.5  million people are suffering from HBV in-
fection in Iran, of whom15% to 40% (1) are at risk of 
developing cirrhosis and/or hepatocellular carcino-
ma (HCC) without intervention (4, 5). They also esti-
mated that 225,000 to 600,000 Iranian chronic HBV 
carriers are at risk of serious health problems related 
to HBV infection and need immediate attention (1). 
Other patients are HBsAg positive carriers that may 
disseminate infection to healthy people vertically or 
horizontally. Moreover, 51% to 56% of Iranian cir-
rhotic patients are HBsAg positive (6, 7). The most 
common routes of transmission reported in national 
surveys are perinatal transmission and intravenous 
drug abuse (8). The geographic distribution of HBV 
infection in Iran showed heterogeneous patterns 
with the highest prevalence rates (more that 3% of 
the population) in northeastern region of the country 
while central and western regions showed the lowest 
prevalence rates (1% to 2%) (1).
Different epidemiological studies with alternative 
methodologies have been taken place to find out the 
risk factors and the routes of transmission of hepati-
tis B virus in Iran. Factors predicting HBV infection 
included family history of hepatitis B infection, his-
tory of receiving blood transfusion, hospitalization, 
unsafe sex, male gender, and living in city area (3, 
8-10).
A national-wide Iranian study had undertaken for 
HBV genotyping between 2006 and 2011 by Iranian 
Hepatitis Network and Hepatitis B laboratory at 
Tehran University of Medical sciences, 360 sam-
ples from different regions and ethnic groups. An 
extensive molecular analysis based on surface genes 
and proteins of isolates carried out as a whole which 
published in recent years.  However, the details of 
differences of molecular analysis between provinc-
es have not published yet. Therefore, the aim of this 
study was to summarize the data extracted from de-
mographic, biochemical, serological/molecular epi-
demiology analysis among different ethnic groups of 
Iranian HBV chronic carriers.
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ABSTRACT 
 
Background and Objectives:  Iranian chronic HBV carrier’s population has shown a unique pattern of genotype D distri-
bution all around the country. The aim of this study was to explore more details of evolutionary history of carriers based on 
structural surface proteins from different provinces.
Materials and Methods: Sera obtained from 360 isolates from 12 Different regions of country were used for amplification 
and sequencing of surface proteins. A detailed mutational analysis was undertaken. 
Results: The total ratio for Missense/Silent nucleotide substitutions was 0.96. Sistan and Kermanshah showed the lowest rate 
of evolution between provinces (P = 0.055). On the other hand, Khorasan Razavi and Khoozestan contained the highest ratio 
(P = 0.055). The rest of regions were laid between these two extremes. Azarbayjan and Guilan showed the highest proportion 
of immune epitope distribution (91.3% and 96%, respectively). Conversely, Sistan and Tehran harbored the least percentage 
(66.6% and 68.8%, respectively). Kermanshah province contained only 5.2%, whereas Isfahan had 54.5% of B cell epitope 
distribution. In terms of T helper epitopes, all provinces showed a somehow homogeneity: 22.58% (Fars) to 46.6% (Khuz-
estan). On the other hand, distribution of substitutions within the CTL epitopes showed a wide range of variation between 
6.6% (Khuzestan) and 63% (Kermanshah).
Conclusion: Further to low selection pressure found in Iranian population, the variations between different regions designate 
random genetic drift within the surface proteins. These finding would have some applications in terms of specific antiviral 
regimen, design of more efficient vaccine and public health issues.
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MATERIALS AND METHODS
360 HBsAg-positive chronic carriers who were 
referred to the Iranian Hepatitis Network (2004-
2010) were enrolled in a cross-sectional study. Dif-
ferent regions based on population and geographical 
zones were chosen to cover the whole ethnic parts 
of country (Table 1). The capital city, Tehran, with a 
population around 13 million was chosen as a versa-
tile multi-cultural and multi-ethnic region without a 
definite ethnic background. All patients were known 
chronic carriers. They had no evident of co-infec-
tion with other hepatitis virus, human immunodefi-
ciency virus (HIV), and they were treatment-naive. 
The diagnosis of chronic liver disease was made by 
clinical, biochemical, radiological and endoscopic 
criteria. 5 ml aliquots of whole blood samples were 
withdrawn from each participant. Serum was, asep-
tically, separated. All sera were referred to Hepatitis 
B Laboratory, School of public Health for serological 
and molecular analysis. The methodology was iden-
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tical for all specimens. The HB viral DNA was ex-
tracted from 200 µl of sera using Qiagen Mini Blood 
Kit (Qiagen, Hilden, Germany) according to manu-
facturer’s instruction. DNA was eluted using 100 µl 
of elution buffer, stored at -20°C. Polymerase chain 
reaction (PCR) was carried out in 100 µl of a mixture 
containing 5 µl of the extracted DNA using standard 
methods. The complete surface gene was amplified 
using S1, S2, S6 and S7 primers which included the 
region of surface gene specifying HBV genotypes/
subtype (amino acid positions 122-160). Direct 
sequencing of surface gene was carried out (Genet-
ic Analyzer ABI- 3130 DNA Sequencer, Fostercity, 
CA, USA) using 2 pmol of appropriate primers: S6C 
and S7D for surface gene. The electropherograms 
were examined visually using Chromas program.
Sequences of surface gene were aligned using the 
BioEdit Package version 7.0.9. 312 sequences were 
submitted to Genbank, under individual accession 
number (Table 1). 
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Ethnic group
Azari
Khorasan
Guilan
Kurdish
Fars
Hormozgan
Balooch
Khoozestan
Isfahan
Tehran
Total
Region
(North-west)
(North-East)
(North)
(West)
(South)
(South)
(South-East)
(South-West)
(Center)
(Center, Capital)
Number of samples
17
37
5
46
19
17
21
12
19
119
312
Accession Number
HM348619-35
GU938342-61, 63-64
HQ008867-68
KC176161-72
KC176137-41
HM348636-81
KC176142-60
GU938305-12, 14-22
HM348694-714
HM348682-93
GU938323-41
KC176076-99
KC176100-30
HM358277-99
HM358300-29
HM358335-39
KC176131-36
Table 1. Origin of 360HBsAg-positive sera that were used as the source for HBsAg mutational analysis (312 sequences were 
submitted to Genbank)
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In addition, it was possible to identify the level of S 
proteins evolution between isolates by measuring the 
mutation frequency (Missense/Silent, dN/dS) of in-
dividual sequences. The average mutation frequency 
of all sequences was 0.96 according to the number of 
mutations per site. The total number of amino acid 
substitutions was 542, of which 404 (74.5%) were dis-
tributed in known immune epitopes of surface protein 
(Table 2). The average amino acid mutation frequency 
was 1.68 mutations per sample. There was a probabil-
ity of 0.74% for substitution per amino acid position.
   Comparison of evolution history of HBsAg be-
tween provinces. Previous results as a whole were 
presented elsewhere (12). The results obtained from 
the comparison between amino acid substitutions and 
demographic, biochemistry and type of substitutions 
among provinces showed no significant associations 
between the number of amino acid mutations with 
age, gender and the ALT levels of chronic carriers. 
On the other hand, strong correlations were found be-
tween the HBeAg status of the patients and the occur-
rence of amino acid substitutions; a significant pro-
portion of such changes occurred in anti-HB epositive 
individuals. Moreover, substantial relationships were 
found between the occurrence of mutations within and 
outside of surface protein immune epitope residues, a 
majority were occurred in anti-HBe positive patients. 
Also, comparison between the distribution of amino 
acid mutations within the B, Th and CTL epitopes 
among provinces showed considerable variations.
   Provinces comparison. In terms of evolutionary 
history of HBV among different population (Table 
2), due to great divergence between results obtained 
for all provinces, a precise molecular analysis was 
carried out on individual patients in each region, 
instead of individual provinces. Results showed that 
ignoring small, non-significant differences, almost all 
locations showed a homogenous pattern (results not 
shown). The exception was non-synonymous/ synon-
ymous (dN/dS) ratio. Sistan and Kermanshah showed 
the least ration of evolution between provinces (0.62 
and 0.73, respectively, P = 0.055). On the other hand, 
Khorasan Razavi and Khoozestan contained the high-
est ratio (2.29 and 1.5, respectively, P = 0.055). The 
rest of regions were laid between these two extremes.
     The distribution of amino acid changes showed that 
of 542 mutated residues, 404 (74.5%) were occurred 
in immune epitopes (Table 2), a novel finding that has 
For the purpose of mutational analysis, we used 
a genotype D sequence isolated from New Guin-
ea reported by Okomoto et al. (accession number 
AB033559). Our previous search for the best com-
parable sequence has led to the selection of this iso-
late as the best fit reference sequence for comparison 
alignment. The differences between this isolate and 
Iranian were only one and six mismatches in terms 
of amino acid and nucleotide, respectively. The dis-
tributions of amino acid changes were determined 
according to known immune epitope residues of 
HBsAg (11). For the purpose of evolutionary history 
study of isolates, previously we used Silent/Missense 
(dS/dN) ratio. For a more clear analysis we used Mis-
sense/Silent (dN/dS) ratio in this study.
 
RESULTS
    Basic characteristics. 360HBsAg-positive chron-
ic patients were enrolled in this study; all were 
native residents between different regions of Iran. All 
were chronic carriers, HBV DNA positive and treat-
ment-naive. 247(68.61%) were male and 113 (31.38%) 
were female with a mean age of 36.34 ±12.42 
(mean±SD). The mean ALT and viral load level were 
81.95 ± 64.85 IU/L (mean±SD) and 15000 copy/mL, 
respectively (results not shown). 20.5%(n=74) and 
68.8% (n=248) were HBeAg and anti-HBe positive, 
respectively. Also 9.72% (n=35) and 0.83% (n=3) were 
negative and positive for both markers, respectively. 
    Genotyping results. The results of the first large 
phylogenetic tree (contained all the studied-sequenc-
es) revealed that Iranian HBV isolates were of gen-
otype D, supported by 95% bootstrap value (1,000 
replicates, results not shown). Phylogenetic analy-
sis of 360 complete surface genes could distinguish 
five sub-genotypes, D (100%); sub-genotypes were 
D1:97.7% (n = 352), D2: 0.55% (n = 2), D3: 0.27% 
(n = 1), D5: 0.83% (n = 3) and D8: 0.55% (n = 2). 
Finally, all isolates belonged to subtype ayw2 (100%) 
(Results not shown).    Surface protein evolution history as a whole. In 
total, 222 (61.6%) out of 360 patients contained at 
least one amino acid mutation. In all, 1104 “nucleo-
tide mutations” occurred, of them 542 (49.1%) were 
missense (amino acid altering) and 562 (50.9%) were 
silent (no amino acid changing) (results not shown). 
http://ijm.tums.ac.ir
Total
360
0.96
-1.68 
(0.74)
 74.5%
25.4%
27.7%
27.4%
48.7%
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not been reported for treatment/vaccine naive chronic 
HBV patients so far. Azarbayjan and Guilan showed 
the highest proportion of immune epitope distribution 
(91.3% and 96%, respectively). Conversely, Sistan 
and Tehran harbored the least percentage (66.6% and 
68.8%, respectively).
    112 (27.7%), 111 (27.4%) and 197 (48.7%) of mu-
tations which clustered within immune epitopes were 
localized to B, T helper and CTL epitopes within the 
surface protein, respectively. Distribution of amino 
acid substitution within the B cell epitope (residue 
100-160) showed that Kermanshah province con-
tained only 5.2%, whereas Isfahan had 54.5% of such 
distribution. In terms of T helper epitopes, all provinc-
es showed a somehow homogeneity; 22.58% (Fars) to 
46.6% (Khuzestan). On the other hand, distribution of 
substitutions within the CTL epitopes showed a wide 
range of variation between 6.6% (Khuzestan) and 
63% (Kermanshah). For more molecular details as a 
whole, readers refer to the previous report (12).
Table 2. Details of mutational analysis from different provinces
Tehran
143
1.08
-1.89 
(0.84)
68.8%
31.1%
19.1%
25.3%
55.4%
Sistan
21
0.62
-0.71 
(0.32)
66.6%
33.3%
50%
40%
10%
Khuzestan
12
1.5
-1.42 
(0.63)
88.2%
11.7%
46.6%
46.6%
6.6%
Khorasan 
Razavi
14
2.29
-4.29
(1.90)
81.6%
18.3%
28.5%
26.5%
44.9%
Southern 
Khorasan
25
0.77
-0.59
(0.26)
83.3%
16.6%
26.6%
33.3%
40%
Kermanshah
46
0.73
-1.04
(0.46)
79.1%
20.8%
5.2%
31.5%
63.1%
Isfahan
19
1
-1.58 
(0.70)
73.3%
26.6%
54.5%
22.7%
22.7%
Hormozgan
18
0.75
-1.67
(0.74)
 80%
20%
37.5%
33.3%
29.1%
Fars
19
1.25
-2.26
(1)
 72%
27.9%
41.9%
22.5%
35.4%
Mazandaran
21
10
100%
0%
100%
 0%
0%
Guilan
5
1.52
-5
(2.21)
 96%
4%
4.1%
37.5%
58.3%
Azarbayjan
17
0.8
-1.35 
(0.60)
 91.3%
8.6%
14.3%
38%
47.7%
Number of 
samples
Missense :  
Silent ratio
Mean of amino 
acid  
substitutions per 
site (%)
Percent of 
amino acid 
substitutions in 
immune  
epitopes
Percent of 
amino acid 
substitutions in 
non-immune 
epitopes
Percent of 
amino acid 
substitutions in 
B cell immune 
epitopes 
Percent of  
amino acid 
substitutions in 
T helper cell im-
mune epitopes 
Percent of 
amino acid 
substitutions in 
CTL immune 
epitopes 
http://ijm.tums.ac.ir
DISCUSSION
   According to CDC classification for the worldwide 
prevalence of HBV, Iran has been located as interme-
diate area with a mean prevalence of 2.14. This article 
represents the molecular data based on comparison 
between 360 chronicin active patients from 12 differ-
ent parts of Iran. The proportion of amino acid muta-
tion in present reports showed that as high as 61.6% 
of chronic HBV patients obtain at least one amin oac-
id mutation within the structural surface protein. This 
finding is much higher than other reports obtained 
from genotypes B, C and D worldwide. The impact 
of these genotypic alterations on the pathogenesis of 
HBV in chronic carriers phenotypically deserves fur-
ther in vitro investigations.
    Our previous reports on these samples indicated that 
a majority of such changes occurred in anti-HBe pos-
itive cases (13-15). Transition from HBeAg positivity 
to anti-HBe positivity is somehow a prolonged pro-
cess, during which a number of amino acid changes 
are proportional to the interaction between virus and 
host immune status. Not surprising, it seems that  in 
the presence of host immune surveillance, the occur-
rence of such mutations is inevitable (14).
     Comparison of evolutionary changes within surface 
proteins between different provinces showed that Kho-
rasan Razavi contained the most versatile features of 
mutation. On the other hand South Khorasan (North-
East) and Sistan-Baloochestan Provinces showed the 
less variable features (along with Kermanshah and 
Hormozgan). We already discussed that the low evo-
lutionary history found in Sistan Baloochestan and 
South Khorasan (14, 16).We assume that eastern bor-
der of Iran which include these provinces contains a 
different history of HBV evolution compared to other 
parts of country. We already hypothesized that the rea-
son for  low prevalence of HBV liver disease compli-
cations in these two regions, might be related to slow 
rate of substitutions (regardless of being synonymous 
or non-synonymous) during the course of chronicity 
(14, 16). Obviously, we cannot exclude the same hy-
pothesis for other regions who contained Missense/
Silent (dN/dS)ratio <1 (see Table 2), however, details 
of molecular analysis in these parts and the nature of 
amino acid substitutions were distinguished Eastern 
part from other regions with somehow the same ratio.
   One of interesting features in the present study which 
make it different from other published data on chron-
ic HBV carriers is the unique pattern of amino acid 
distribution in CTL epitopes (47.8%) and on the other 
hand, a low prevalence of “a” determinant variation in 
the surface proteins from 61.6% carriers. Previous in-
vestigation showed a prevalence of 10.8% and 11.2% 
of HBsAg variation in chronic carriers, mainly located 
within the “a” determinant (17-19). All reported sur-
veys from Iran showed that the only HBV genotype is 
D. Is there any correlation between this unique pattern 
of genotype and the number and the nature of distribu-
tion of amino acid changes? To answer this question, 
other similar investigations from other parts of worlds 
which contain the genotype D predominant is need-
ed to avoid bias on recombination between genotype 
D and other genotypes. The best candidate would be 
the sequences from countries of Caucasian origin like 
Turkey, Pakistan and India with prevalence of geno-
type D being: 87%, 62% and 67%, respectively (20). 
We did not find similar results on comparison between 
available surface proteins in international databases. 
Therefore, we assume that Iranian genetic background 
(perhaps types of HLA) might be responsible for a 
high number of amino acid changes in surface protein 
despite being chronic carriers. We already hypothe-
sized that differences in distribution of HLA antigens, 
or other immune genes between diverse geographical 
areas probably contributed to the selection of amino 
acid variation (21).
   In keeping with circulation of HBV amongst Ira-
nian ethnic group sit seems that after seroconversion 
to anti-HBe, no further selection pressure exists for 
substitutions in surface proteins among other geno-
type D-infected ethnic groups (other non-Iranian Cau-
casians). The same situation is true for Iranian ethnic 
group, as the total (dN/dS) ratio was 0.96, indicating a 
natural negative selection pressure. However, we be-
lieve that in the long term of progression of chronicity 
and as time goes by, random genetic drift is responsi-
ble for such high number (and also the distribution of 
amino acids). In fact,  once a mutation has arisen in a 
population what determine the outcome ( to be fixed 
or to be lost),  is not always down to how much bet-
ter or worse it is (natural selection) compared to those 
variations already present in the population; instead 
it may simply be down to chance. As random genet-
ic drift observed most strongly in small populations, 
substitutions of amino acid in various regions of coun-
try with versatile features of B, Th and CTL epitopes 
distribution (see Table 2) designate this unique muta-
tional profile. Does this phenomenon related to either 
viral (uniqueness of genotype D) or host (Iranian HLA 
HBSAG EVOLUTION IN IRAN
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types) factors need to be explored in the future, ap-
plying longitudinal, cohort studies including patients 
from different phases of chronicity (before and after 
HBeAg seroconversion).
    In conclusion, the significance of unique pictures of 
mutational distribution despite low evolutionary rate 
in Iranian chronic carriers came up from the present 
study would have some applications in terms of specif-
ic antiviral regimen, design of more efficient vaccine 
and public health issues in the next future.
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